1-2 of 2
Kim Blenman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC

Julia Foldi, Adriana Kahn, Andrea Silber, Tao Qing, Emily Reisenbichler, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Anees Chagpar, Tristen Park, Adam Blanchard, Kim Blenman, David L. Rimm, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3720–3728.
https://doi.org/10.1158/1078-0432.CCR-22-0862
Published: 01 September 2022
View article titled, Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC
Open the PDF for Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC in another window
Includes: Supplementary data
Journal Articles

PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer

Fahad Shabbir Ahmed, Patricia Gaule, John McGuire, Katir Patel, Kim Blenman, Lajos Pusztai, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5456–5461.
https://doi.org/10.1158/1078-0432.CCR-20-1303
Published: 15 October 2020
View article titled, PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
Open the PDF for PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer in another window
Includes: Supplementary data